This NDC is on FDA's drug shortage list (posted Feb 20, 2018)
Reported reason: Demand increase for the drug
Product Information
LIDOCAINE HCL 2% 100 MG/5 ML is a generic product labeled by Eugia US LLC, priced at $0.3487 per ML under NDC 55150016505. Its NADAC has been published 164 times since Sep 21, 2022.
FDA first approved this application on Mar 14, 2013. Its Orange Book therapeutic-equivalence code is AP.
Strength
20 mg/mL
Manufacturer
Eugia US LLCNDC
55150016505
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
EPIDURAL; INFILTRATION; INTRACAUDAL; PERINEURAL
Effective Date
7/22/2026
Active Ingredients
LIDOCAINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203082FDA Approved
3/14/2013
TE Code
AP
On Market Since
3/14/2013
Pharmacological Classes
Price Statistics
The NADAC for LIDOCAINE HCL 2% 100 MG/5 ML has been published 164 times since Sep 21, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3487 per ML |
|---|---|
| All-time high | $0.4109 (Feb 11, 2026) |
| All-time low | $0.3424 (Sep 21, 2022) |
| 52-week high | $0.4109 |
| 52-week low | $0.3487 |
| Median price | $0.3782 |
| Average price | $0.3733 |
| Largest weekly change | +15.4% (Apr 17, 2024) |
| Weeks tracked | 164 |
| Tracking since | Sep 21, 2022 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 78% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eugia US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lidocaine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Amide Local Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LIDOCAINE HCL 2% 100 MG/5 ML?
The current National Average Drug Acquisition Cost (NADAC) for LIDOCAINE HCL 2% 100 MG/5 ML, manufactured by Eugia US LLC, is $0.3487 per ML (NDC 55150016505), effective Sep 30, 2026.
How has the price of LIDOCAINE HCL 2% 100 MG/5 ML changed over time?
Over the history we have for it, the NADAC for LIDOCAINE HCL 2% 100 MG/5 ML has held within roughly two percent of its current level. It has been tracked across 164 weekly CMS publications since Sep 21, 2022.
What are the highest and lowest recorded NADAC prices for LIDOCAINE HCL 2% 100 MG/5 ML?
Since Sep 21, 2022, the NADAC for LIDOCAINE HCL 2% 100 MG/5 ML has ranged from a low of $0.3424 (Sep 21, 2022) to a high of $0.4109 (Feb 11, 2026), with a median of $0.3782 per ML.
Are there cheaper alternatives to LIDOCAINE HCL 2% 100 MG/5 ML?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIDOCAINE HCL 2% VIAL, is $0.0762 per ML — about 78% below LIDOCAINE HCL 2% 100 MG/5 ML.
Who manufactures LIDOCAINE HCL 2% 100 MG/5 ML?
LIDOCAINE HCL 2% 100 MG/5 ML (NDC 55150016505) is labeled by Eugia US LLC, and CMS classifies it as a generic product.
Is LIDOCAINE HCL 2% 100 MG/5 ML in shortage?
Yes — NDC 55150016505 is currently listed in FDA's drug shortage database (posted Feb 20, 2018). Reported reason: Demand increase for the drug.